Prostate Cancer & BPHArchives
Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings
Prostate Cancer & BPH 5 min.
Prostate cancer (PCa) is the second most commonly diagnosed solid malignancy worldwide, with an ever-increasing incidence [1]. The definitive diagnosis of prostate cancer relies on histopathological verification through prostate biopsy. Currently, the indication for prostate biopsy is determined by prostate...
Urinary function, sexual function and quality of life after prostate low-dose-rate brachytherapy: a retrospective analysis
Prostate Cancer & BPH 3 min.
Most cancer treatments carry adverse effects that significantly impact patients' quality of life. The careful estimation of the risks and benefits associated with each treatment option is especially important for cancer patients who are being offered curative treatment. This is especially relevant for...
Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis
Prostate Cancer & BPH 4 min.
Prostate cancer is the second most frequently diagnosed malignancy and the fifth leading cause of cancer-associated death in men worldwide, having a high impact on the health of the world’s population [1, 2]. Various treatment modalities for localized prostate cancer are available, such as active...
A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol
Prostate Cancer & BPH 4 min.
Prostate cancer is the most commonly diagnosed male malignancy, with over 24,000 cases diagnosed in Australia in 2021 [1]. It is responsible for the highest incidence of cancer-related disability worldwide, with a large proportion of such morbidity because of the adverse outcomes associated with over-treatment...
Major adverse cardiovascular events among Black and White Veterans receiving androgen deprivation therapy for prostate cancer: a retrospective cohort study
Prostate Cancer & BPH 5 min.
Prostate cancer (PC), the most common malignancy in American men [1], has excellent long-term survival in those with localized disease (> 99% at 5 years); [1] however, men with advanced, recurrent, or metastatic disease have poorer survival. The cornerstone treatment for high-risk disease includes...
